FILANA THERAPEUTICS, INC.
No enriched coverage for $FLNA in the last 7 days.
Barry Richard (President & CEO) purchased 306,813 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at an average of $0.91 ($0.90–$0.92, $0.28M total) across 2 trades over 2026-09-29 to 2026-09-30.
Barry Richard (President & CEO) purchased 93,091 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.84 on 2026-09-28.
FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio
Recent FLNA coverage spans insider activity, corporate actions and earnings.
In the last 30 days, FLNA insiders filed 3 SEC Form 4 transactions — 3 purchases ($356K) and no sales. The most active reporter was Barry Richard, President & CEO, with 3 filings.
Insider purchase suggests confidence and may create modest buying pressure.
Insider purchase suggests confidence, may create modest buying pressure.
The removal of the hold removes a major regulatory barrier, likely enabling near‑term trial initiation and could lift the stock.
The filing updates liquidity runway and reiterates the key overhang: an FDA clinical hold remains in place for simufilam, shaping near-term risk and valuation.
Board/officer changes and updated compensatory arrangements can affect governance, retention, and near-term sentiment, but the excerpt provides no deal/financial figures.
AlphAI scores every news story that mentions FLNA with an AI model for sentiment and relevance, and aggregates insider trades from FILANA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Barry Richard (President & CEO) purchased 306,813 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at an average of $0.91 ($0.90–$0.92, $0.28M total) across 2 trades over 2026-09-29 to 2026-09-30.
1 min readBarry Richard (President & CEO) purchased 93,091 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.84 on 2026-09-28.
1 min readFILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio
2 min readFILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing
4 min readFILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_975585.htm EXHIBIT 10.1 ex_975585.htm Exhibit 10.1 FILANA THERAPEUTICS, INC. 2018 OMNIBUS INCENTIVE PLAN (CONFORMED COPY THROUGH AMENDMENT NO. 2) 1. Purposes of the Plan . The purposes of this Plan are to attract and retain the best available personnel, to provide ad
2 min read